This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries.The vaccine will provide effective and long-lasting protection for children against pneumococcal diseases. With that thought, we have developed this PCV with a unique composition based on the serotype prevalence in India. ""This makes our PCV an ideal choice for protecting our children from pneumococcal disease. Recognising its widespread fatality, WHO recommends the inclusion of Pneumococcal Conjugate Vaccine (PCV) in routine childhood immunisation programs in all countries. Following this, Polysaccharide Conjugate Vaccines (PCV) work directly to reduce the incidence of pneumococcal pneumonia by preventing Streptococcus pneumonia.Serum Institute is also the pharma company that is testing and producing the Oxford-AstraZeneca Covid-19 vaccine candidate in India.

Source: Economic Times December 28, 2020 11:35 UTC